Angiotensin converting enzyme inhibitors
- 80 Downloads
Inhibition of angiotensin converting enzyme (scace) in patients suffering from renovascular hypertension results in lowering of the blood-pressure. The development of captopril, an orally activeace inhibitor and the structure-activity relationship of captopril analogues are described. Some side effects of captopril were attributed to the presence of an SH-group in the molecule. This led to the development of a series of non-mercaptoace inhibitors derived from captopril. One of them, enalapril, a potentace inhibitor with a long duration of antihypertensive action, is now tested in clinical trials.
KeywordsPublic Health Hypertension Clinical Trial Internal Medicine Angiotensin
Unable to display preview. Download preview PDF.
- Antonaccio, M.J. (1982)Ann. Rev. Pharmacol. Toxicol. 22, 57–87.Google Scholar
- Brunner, D.B., G. Desponds, J. Biollaz, I. Keller, F. Ferber, H. Gavras, H.R. Brunner andJ.L. Schelling (1981)Brit. J. Clin. Pharmacol, 11, 461–467.Google Scholar
- Gavras, H., B. Waeber, I. Gavras, J. Biollaz, H.R. Brunner andR.O. Davies (1981)Lancet II, 543–546.Google Scholar
- Petrillo, E.W., andA. Ondetti (1982)Med. Res. Rev. 2, 1–41.Google Scholar